Bausch + Lomb Corporation (BLCO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Bausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Care Transcript
With consumer sentiment sitting at 53.3 in March 2026, deep in pessimistic territory, retail investors are hunting for defensive names that can grow even as households tighten budgets.
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Brenton L. Saunders CEO | NEO-L Exchange | CA0717051076 ISIN |
| CA Country | 13,500 Employees | - Last Dividend | - Last Split | - IPO Date |
Bausch + Lomb Corporation is a globally recognized eye health company with operations spanning several key markets, including the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and beyond. The company is structured into three main segments: Vision Care, Pharmaceuticals, and Surgical, each catering to different aspects of eye health and treatment needs. Founded in 1853, Bausch + Lomb has established its headquarters in Vaughan, Canada, demonstrating a long-standing commitment to providing innovative eye health solutions. Operating as a subsidiary of Bausch Health Companies Inc., Bausch + Lomb utilizes both direct sales forces and independent distributors to sell its wide array of products and services across the globe.
This segment offers a broad spectrum of contact lenses catering to various wearing modalities, including daily disposable and frequently replaced options. Bausch + Lomb also provides a range of contact lens care products, which includes over-the-counter eye drops, eye vitamins, and mineral supplements targeting conditions like eye allergies, conjunctivitis, dry eye, and redness relief.
In the Pharmaceuticals segment, Bausch + Lomb offers both proprietary and generic pharmaceutical products designed for post-operative treatments, as well as for managing glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. This segment leverages innovative research to develop treatments that address some of the most pressing eye health issues faced by patients worldwide.
This segment focuses on providing medical device equipment, consumables, and technologies needed for treating a variety of eye conditions including cataracts, corneal, vitreous, and retinal issues. Bausch + Lomb offers intraocular lenses and delivery systems, phacoemulsification equipment, and other essential surgical instruments and devices needed for cataract surgery. This demonstrates the company’s commitment to supporting eye surgeons with the tools and technologies needed for effective treatment procedures.